116 related articles for article (PubMed ID: 18495246)
1. An evaluation of the cardiotoxicity of imatinib mesylate.
Ribeiro AL; Marcolino MS; Bittencourt HN; Barbosa MM; Nunes Mdo C; Xavier VF; Clementino NC
Leuk Res; 2008 Dec; 32(12):1809-14. PubMed ID: 18495246
[TBL] [Abstract][Full Text] [Related]
2. Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy.
Tiribelli M; Colatutto A; Marin L; Barbina G; Qualizza U; Damiani D; Toffoletti E; Medeot M; Candoni A; Tonutti E; Sala P; Fanin R
Am J Hematol; 2008 Jun; 83(6):517-8. PubMed ID: 18306359
[No Abstract] [Full Text] [Related]
3. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
Estabragh ZR; Knight K; Watmough SJ; Lane S; Vinjamuri S; Hart G; Clark RE
Leuk Res; 2011 Jan; 35(1):49-51. PubMed ID: 21030079
[TBL] [Abstract][Full Text] [Related]
4. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
Milojkovic D; Short K; Salisbury JR; Creamer D; du Vivier AW; Mufti GJ
Leukemia; 2003 Jul; 17(7):1414-6. PubMed ID: 12835733
[No Abstract] [Full Text] [Related]
5. Hypolipemiant besides antileukemic effect of imatinib mesylate.
Gologan R; Constantinescu G; Georgescu D; Ostroveanu D; Vasilache D; Dobrea C; Iancu D; Popov V
Leuk Res; 2009 Sep; 33(9):1285-7. PubMed ID: 19327828
[TBL] [Abstract][Full Text] [Related]
6. The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia.
Marcolino MS; Ribeiro AL; Clementino NC; Nunes Mdo C; Barbosa MM; Silva MH; Bittencourt HN; Geleijnse ML; Boersma E
Leuk Res; 2011 Mar; 35(3):317-22. PubMed ID: 20692037
[TBL] [Abstract][Full Text] [Related]
7. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients.
Brazzelli V; Prestinari F; Barbagallo T; Rona C; Orlandi E; Passamonti F; Locatelli F; Zecca M; Villani S; Borroni G
J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):384-7. PubMed ID: 17309464
[TBL] [Abstract][Full Text] [Related]
8. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.
Kondo T; Tasaka T; Sano F; Matsuda K; Kubo Y; Matsuhashi Y; Nakanishi H; Sadahira Y; Wada H; Sugihara T; Tohyama K
Leuk Res; 2009 Sep; 33(9):e137-8. PubMed ID: 19371951
[TBL] [Abstract][Full Text] [Related]
9. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
10. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
11. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
12. Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.
Roos C; Stenke L; Ohm L; Widell S; Kumlin M; Lindgren JA; Tornhamre S
Br J Haematol; 2008 Sep; 142(6):992-5. PubMed ID: 18573108
[No Abstract] [Full Text] [Related]
13. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
[No Abstract] [Full Text] [Related]
14. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Uchiyama M; Ikeda T
Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
[No Abstract] [Full Text] [Related]
15. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
16. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Rosti G; Martinelli G; Baccarani M
Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
[No Abstract] [Full Text] [Related]
17. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Atallah E; Kantarjian H; Cortes J
Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
[No Abstract] [Full Text] [Related]
18. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Hatfield A; Owen S; Pilot PR
Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
[No Abstract] [Full Text] [Related]
19. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
[No Abstract] [Full Text] [Related]
20. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
